Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 Additional KT-333 (STAT3) and KT-253 (MDM2) Phase 1 data expected in 2024 Watertown, Mass. (February 22, 2024) – Kymera ...